Indivior
 | |
| Public company | |
| Traded as | LSE: INDV |
| Industry | pharmaceuticals |
| Founded | 1994 |
| Headquarters | Slough, Berkshire |
Key people |
Howard Pien, Chairman Shaun Thaxter, CEO |
| Products | Suboxone |
| Revenue | $1,014 million (2015)[1] |
| $346 million (2015)[1] | |
| $228 million (2015)[1] | |
| Website | www.indivior.com/ |
Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
History
The company was established as the Buprenorphine division of Reckitt Benckiser in 1994.[2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior.[3] By February 2015 the company was capitalised at £2.3 billion on the London Stock Exchange.[4]
Operations
The company's main product is Suboxone, an addiction-control product.[2] Other products include remedies for opioid addiction, cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.[5]
References
- 1 2 3 "Annual Report 2015" (PDF). Indivior. Retrieved 9 April 2016.
- 1 2 "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
- ↑ "RB complete demerger of Indivior - RB". RB. 23 December 2014. Retrieved 21 March 2015.
- ↑ "Is Indivior PLC The Perfect Partner For AstraZeneca plc In Your Portfolio?". Retrieved 22 March 2015.
- ↑ "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.
External links
This article is issued from Wikipedia - version of the 8/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.